Welcome to our dedicated page for MEDICENNA THERA news (Ticker: $MDNAF), a resource for investors and traders seeking the latest updates and insights on MEDICENNA THERA stock.
Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect MEDICENNA THERA's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.
Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of MEDICENNA THERA's position in the market.
Rhea-AI Summary
Medicenna announces the oral presentation of MDNA11 data from the Phase 1/2 ABILITY-1 Study at the 2024 ASCO Annual Meeting. The presentation will feature new and updated clinical data, including bizaxofusp survival results from a recurrent glioblastoma trial. The Company will present two abstracts, one as an oral podium presentation and the other as a poster. The podium presentation will cover results from the ABILITY-1 monotherapy dose escalation study with MDNA11 in patients with advanced solid tumors. The second abstract will provide new data analyses for bizaxofusp survival outcomes compared to a propensity matched external control arm in nonresectable recurrent glioblastoma.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
21.93%
Tags
-
Rhea-AI Summary
Medicenna Therapeutics Corp. presents promising clinical data on MDNA11 at AACR 2024, showing a 29% response rate and 50% clinical benefit rate in advanced solid tumor patients. Notable findings include 100% reduction of target lesions in melanoma and pancreatic cancer patients, durable stable disease in melanoma patients, and no dose-limiting toxicities reported. MDNA11 demonstrates compelling single-agent activity, with expansion of the study to new sites in the US and Korea.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
33.03%
Tags
-
Rhea-AI Summary
Medicenna Therapeutics Corp. announces new preclinical data on MDNA113, a novel T-MASK candidate targeting IL-13Rα2, presented at the 2024 AACR Annual Meeting. MDNA113 aims to deliver two immunotherapies to cancer fighting immune cells in the tumor micro-environment, showing promising results in tumor accumulation and tolerability.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-16.79%
Tags
Rhea-AI Summary
Medicenna Therapeutics Corp. announced Dr. Fahar Merchant's participation at the 2024 Bloom Burton & Co. Healthcare Investor Conference. The event aims to provide updates on the development of Superkines and offers opportunities for corporate updates and private meetings with investors.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-7.3%
Tags
-
Rhea-AI Summary
Medicenna Therapeutics Corp. announces the presentation of pre-clinical data on MDNA113 and an update on Phase 1/2 ABILITY-1 Study at AACR 2024. MDNA113 is a novel tumor-targeted bi-functional anti-PD1-IL-2 Superkine. MDNA11, a long-acting IL-2 super-agonist, shows promising anti-tumor activity in advanced solid tumors.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.37%
Tags
-
News
Rhea-AI Summary
Medicenna Therapeutics Corp. announces positive results from the ABILITY-1 study for MDNA11, showing a 23% response rate and promising clinical data. The company also extends its cash runway and outlines strategic plans for 2024.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
27.27%
Tags
Rhea-AI Summary
Medicenna Therapeutics Corp. announces the first patient dosed in the combination arm of the Phase 1/2 ABILITY study evaluating MDNA11 with KEYTRUDA for advanced solid tumors. MDNA11 shows promising single-agent activity and potential synergistic effects with KEYTRUDA. The company expects to report results from the study arms in H1 and H2 2024.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.02%
Tags
-
Rhea-AI Summary
Medicenna Therapeutics Corp. announced the appointment of MNP LLP as its new auditor, replacing PricewaterhouseCooper LLP. The Former Auditor's report for the two most recently completed financial years showed no reservations or modified opinions. The company's board of directors and audit committee approved the resignation of the Former Auditor and the appointment of MNP. Additionally, Medicenna has engaged Tandem Accounting Group Ltd. to manage its financial reporting and internal bookkeeping requirements on a contract basis.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
-
Rhea-AI Summary
Medicenna Therapeutics Corp. (MDNA) announced the initiation of enrollment in the combination arm of the Phase 1/2 ABILITY study evaluating MDNA11, a long-acting IL-2 Superkine, in combination with KEYTRUDA for the treatment of advanced solid tumors. The study aims to evaluate the potential synergistic effect of MDNA11 with KEYTRUDA in patients who do not respond or develop resistance to checkpoint therapy. MDNA11 has shown encouraging single-agent activity and is generally well tolerated. The company expects to report initial results from both the monotherapy expansion and combination escalation arms of the Phase 2 study in the first half of 2024.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.54%
Tags
Rhea-AI Summary
Medicenna Therapeutics Corp. (MDNA) announces its shares will commence trading on the OTCQB Venture Market in the United States, effective December 19, 2023, while continuing to trade on the Toronto Stock Exchange under its symbol MDNA. The OTCQB is the primary platform for U.S. and international companies in the entrepreneurial and development stages, providing a high-quality trading and information experience for U.S. investors.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.64%
Tags
MEDICENNA THERA CORP
OTC:MDNAF
MDNAF Rankings
MDNAF Stock Data
99.71M
44.35M
23.68%
7.86%
0.16%
Pharmaceutical Preparation Manufacturing
Manufacturing
United States of America
Toronto
About MDNAF
medicenna is a clinical stage immunotherapy company developing novel highly selective versions of il-2, il-4 and il-13 superkines and first in class empowered cytokines (ecs). our mission is to become the leader in the development and commercialization of targeted ecs and superkines for the treatment of a broad range of cancers and immune-mediated diseases. we seek to achieve these successful treatments by drawing on our expertise, and that of world-class collaborators, to develop a unique set of superkines. these superkines can be developed either on their own as short or long-acting therapeutics or fused with pro-apoptotic proteins in order to precisely deliver potent cell-killing agents to the cancer cells as well as the immunosuppressive tumor micro-environment and the cancer stem cells without harming healthy cells. superkines can also be fused with other types of proteins such as antibodies to generate novel “immunocytokines” or combined with other treatment modalities such as ca